Completed PHASE1 INTERVENTIONAL 1-arm NCT00740727

EASI Access II --- Follow-up Study to the EASI Access Trial

Enzymatically Augmented Subcutaneous Infusion (EASI) Access II Trial

Sponsor: Baxter Healthcare Corporation

Conditions Dehydration Difficult Intravenous Access Disaster Medicine

Interventions Enzymatically Augmented Subcutaneous Infusion (EASI) line placement Human recombinant hyaluronidase (HRH)

Updated 7 times since 2017 Last updated: Sep 10, 2009 Started: Feb 28, 2009 Primary completion: Mar 31, 2009 Completion: Mar 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Dehydration and Difficult Intravenous Access and is currently completed. Baxter Healthcare Corporation leads this study, which shows 7 recorded versions since 2009 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Apr 2022 — Jul 2024 [monthly]

Completed PHASE1
Jan 2021 — Apr 2022 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Feb 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Baxter Healthcare Corporation
Massachusetts General Hospital

Data source: Massachusetts General Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Boston, United States